Excitotoxicity and bioenergetics in glutaryl-CoA dehydrogenase deficiency

被引:37
|
作者
Kölker, S
Koeller, DM
Sauer, S
Hörster, F
Schwab, MA
Hoffmann, GF
Ullrich, K
Okun, JG
机构
[1] Univ Childrens Hosp, Dept Gen Pediat, Div Metab & Endocrine Dis, D-69120 Heidelberg, Germany
[2] Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR USA
[4] Univ Med Ctr, Dept Gen Paediat, Hamburg, Germany
关键词
D O I
10.1023/B:BOLI.0000045762.37248.28
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Glutaryl-CoA dehydrogenase deficiency is an inherited organic acid disorder with predominantly neurological presentation. The biochemical hallmark of this disease is an accumulation and enhanced urinary excretion of two key organic acids, glutaric acid and 3-hydroxyglutaric acid. If untreated, acute striatal damage is often precipitated by febrile illnesses during a vulnerable period of brain development in infancy or early childhood, resulting in a dystonic dyskinetic movement disorder. 3-Hydroxyglutaric and glutaric acids are structurally similar to glutamate, the main excitatory amino acid of the human brain, and are considered to play an important role in the pathophysiology of this disease. 3-Hydroxyglutaric acid induces excitotoxic cell damage specifically via activation of N-methyl-D-aspartate receptors. It has also been suggested that secondary amplification loops potentiate the neurotoxic properties of these organic acids. Probable mechanisms for this effect include cytokine-stimulated NO production, a decrease in energy metabolism, and reduction of cellular creatine phosphate levels. Finally, maturation-dependent changes in the expression of neuronal glutamate receptors may affect the vulnerability of the immature brain to excitotoxic cell damage in this disease.
引用
收藏
页码:805 / 812
页数:8
相关论文
共 50 条
  • [31] Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency
    Koelker, Stefan
    Garbade, Sven F.
    Greenberg, Cheryl R.
    Leonard, James V.
    Saudubray, Jean-Marie
    Ribes, Antonia
    Kalkanoglu, H. Serap
    Lund, Allan M.
    Merinero, Begona
    Wajner, Moacir
    Troncoso, Monica
    Williams, Monique
    Walter, John H.
    Campistol, Jaume
    Martí-Herrero, Milagros
    Caswill, Melissa
    Burlina, Alberto B.
    Lagler, Florian
    Maier, Esther M.
    Schwahn, Bernd
    Tokatli, Aysegul
    Dursun, Ali
    Coskun, Turgay
    Chalmers, Ronald A.
    Koeller, David M.
    Zschocke, Johannes
    Christensen, Ernst
    Burgard, Peter
    Hoffmann, Georg F.
    PEDIATRIC RESEARCH, 2006, 59 (06) : 840 - 847
  • [32] SPECTROELECTROCHEMICAL AND RESONANCE RAMAN INVESTIGATIONS OF GLUTARYL-COA DEHYDROGENASE
    BYRON, CM
    HUSAIN, M
    BRENNAN, B
    STANKOVICH, MT
    BIOCHEMISTRY, 1988, 27 (08) : 3096 - 3096
  • [33] Natural History, Outcome, and Treatment Efficacy in Children and Adults with Glutaryl-CoA Dehydrogenase Deficiency
    Stefan Kölker
    Sven F Garbade
    Cheryl R Greenberg
    James V Leonard
    Jean-Marie Saudubray
    Antonia Ribes
    H Serap Kalkanoglu
    Allan M Lund
    Begoña Merinero
    Moacir Wajner
    Mónica Troncoso
    Monique Williams
    John H Walter
    Jaume Campistol
    Milagros MartÍ-Herrero
    Melissa Caswill
    Alberto B Burlina
    Florian Lagler
    Esther M Maier
    Bernd Schwahn
    Aysegul Tokatli
    Ali Dursun
    Turgay Coskun
    Ronald A Chalmers
    David M Koeller
    Johannes Zschocke
    Ernst Christensen
    Peter Burgard
    Georg F Hoffmann
    Pediatric Research, 2006, 59 : 840 - 847
  • [34] Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency
    Hoffmann, GF
    Athanassopoulos, S
    Burlina, AB
    Duran, M
    deKlerk, JBC
    Lehnert, W
    Leonard, JV
    Monavari, AA
    Muller, E
    Muntau, AC
    Naughten, ER
    PleckoStarting, B
    SupertiFurga, A
    Zschocke, J
    Christensen, E
    NEUROPEDIATRICS, 1996, 27 (03) : 115 - 123
  • [35] Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)
    Koelker, S.
    Christensen, E.
    Leonard, J. V.
    Greenberg, C. R.
    Burlina, A. B.
    Burlina, A. P.
    Dixon, M.
    Duran, M.
    Goodman, S. I.
    Koeller, D. M.
    Mueller, E.
    Naughten, E. R.
    Neumaier-Probst, E.
    Okun, J. G.
    Kyllerman, M.
    Surtees, R. A.
    Wilcken, B.
    Hoffmann, G. F.
    Burgard, P.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (01) : 5 - 22
  • [36] THE CLINICAL, BIOCHEMICAL AND MOLECULAR FEATURES OF THREE IRANIAN PATIENTS WITH GLUTARYL-COA DEHYDROGENASE DEFICIENCY
    Tehrani, Saeed
    Zaman Dr
    Houshmand Dr
    JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S140 - S140
  • [37] DEFICIENCY OF GLUTARYL-COA OXIDASE - A NEW PEROXISOMAL DISORDER
    BENNETT, MJ
    POLLITT, RJ
    HALE, DE
    GOODMAN, SI
    VAMECQ, J
    PEDIATRIC RESEARCH, 1991, 29 (04) : A127 - A127
  • [38] EARLY PRENATAL-DIAGNOSIS IN 2 PREGNANCIES AT RISK FOR GLUTARYL-COA DEHYDROGENASE-DEFICIENCY
    HOLME, E
    KYLLERMAN, M
    LINDSTEDT, S
    JOURNAL OF INHERITED METABOLIC DISEASE, 1989, 12 : 280 - 282
  • [39] Development of pathogenic concepts in glutaryl-CoA dehydrogenase defficiency: The challenge
    Goodman, SI
    JOURNAL OF INHERITED METABOLIC DISEASE, 2004, 27 (06) : 801 - 803
  • [40] Glutaconyl-CoA is the main toxic agent in glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I)
    Lehnert, W
    Sass, JO
    MEDICAL HYPOTHESES, 2005, 65 (02) : 330 - 333